J. TarningN. LindegardhS. SandbergN. J.P. DayN. J. WhiteM. AshtonGoteborg University, Sahlgrenska AcademyMahidol UniversityChurchill Hospital2018-07-122018-07-122008-01-01Journal of Pharmaceutical Sciences. Vol.97, No.8 (2008), 3400-341015206017002235492-s2.0-52449086887https://repository.li.mahidol.ac.th/handle/20.500.14594/19884This study aimed to evaluate the pharmacokinetic properties of pipera-quine in the rat after intravenous and oral administration, and to identify and characterize the main piperaquine metabolites in rat plasma, urine, faeces and bile after intravenous administration. Male Sprague - Dawley rats were administered piperaquine as an emulsion orally or as a short-term intravenous infusion. Venous blood for pharmacokinetic evaluation was frequently withdrawn up to 90 h after dose. Urine, bile and faeces were collected after an infusion in rats kept in metabolic cages or in anesthetized rats. Pharmacokinetic characterization was done by compartmental modeling and non-compartmental analysis using WinNonlin. Piperaquine disposition was best described by a 3-compartment model with a rapid initial distribution phase after intravenous administration. The pharmacokinetics of piperaquine was characterized by a low clearance, a large volume of distribution and a long terminal half-life. Piperaquine displayed a low biliary clearance and less than 1% of the total dose was recovered in urine. The absolute oral bioavailability was approximately 50%. The main metabolite after intravenous administration of piperaquine was a carboxylic acid product identical to that reported in humans. The similarity with results in humans indicates the rat to be a suitable species for nonclinical in vivo piperaquine studies. © 2007 Wiley-Liss, Inc. and the American Pharmacists Association.Mahidol UniversityPharmacology, Toxicology and PharmaceuticsArticleSCOPUS10.1002/jps.21226